Pharmacological Evaluation of Novel Hydrazide and Hydrazone Derivatives: Anti-Inflammatory and Analgesic Potential in Preclinical Models
Molecules · 26.03.2025 · 30 (7) · 1472
DOI: 10.3390/molecules30071472 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 26.03.2025. Verfasst von Hristina Zlatanova-Tenisheva und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Clinical Pharmacology, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria. Hauptthemen laut MEDLINE: Hydrazones, Analgesics, Hydrazines, Anti-Inflammatory Agents. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union-NextGenerationEU, through the National Recovery and Resilience Plan of the Republic of Bulgaria, European Union-NextGenerationEU.
Abstract (Originalsprache)
Hydrazones, characterized by their C=N–NH functional group, are promising candidates in medicinal chemistry due to their ability to interact with biological targets. This study evaluated the anti-inflammatory and analgesic properties of N-pyrrolylcarbohydrazide (1) and four pyrrole hydrazone derivatives (1A–D) in male Wistar rats (6 weeks old). Anti-inflammatory activity was assessed using a carrageenan-induced paw edema model, while formalin, tail flick, and paw withdrawal tests evaluated analgesia. Compound 1 exhibited dose-dependent anti-inflammatory activity. At 20 mg/kg, significant edema reductions were observed at the 2nd (p = 0.035) and 3rd hours (p = 0.022), while at 40 mg/kg, reductions remained significant at the 2nd (p = 0.008) and 3rd hours (p = 0.046). Compound 1A showed pronounced effects at 20 mg/kg at the 2nd (p = 0.005), 3rd (p < 0.001), and 4th hours (p = 0.004). Other compounds demonstrated minimal or no activity. Analgesic evaluation revealed that at 40 mg/kg, compound 1 significantly reduced paw-licking time in the second phase (p = 0.038). Compounds 1B, 1C, and 1D exhibited transient effects in the first phase only (p < 0.05). Compound 1A lacked significant analgesic activity. The findings suggest that structural modifications may enhance efficacy for broader therapeutic applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Clinical Pharmacology, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.
- Department of Organic Synthesis, University of Chemical Technology and Metallurgy, 1756 Sofia, Bulgaria.
ORCID-Profile: Hristina Zlatanova-Tenisheva, Stanislava Vladimirova
Förderung
- European Union-NextGenerationEU, through the National Recovery and Resilience Plan of the Republic of Bulgaria
- European Union-NextGenerationEU
Zitieren
APA
Zlatanova-Tenisheva, H., & Vladimirova, S. (2025). Pharmacological Evaluation of Novel Hydrazide and Hydrazone Derivatives: Anti-Inflammatory and Analgesic Potential in Preclinical Models. Molecules, 30(7), 1472. https://doi.org/10.3390/molecules30071472
Vancouver
Zlatanova-Tenisheva H, Vladimirova S. Pharmacological Evaluation of Novel Hydrazide and Hydrazone Derivatives: Anti-Inflammatory and Analgesic Potential in Preclinical Models. Molecules. 2025;30(7):1472. doi:10.3390/molecules30071472
BibTeX
@article{ZlatanovaTenisheva2025,
author = {Zlatanova-Tenisheva, Hristina and Vladimirova, Stanislava},
title = {Pharmacological Evaluation of Novel Hydrazide and Hydrazone Derivatives: Anti-Inflammatory and Analgesic Potential in Preclinical Models},
journal = {Molecules},
year = {2025},
volume = {30},
number = {7},
pages = {1472},
doi = {10.3390/molecules30071472}
}
EUVIMED